2026 Q1 -tulosraportti
UUTTA
5 päivää sitten
‧1 t 1 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 685 | - | - | ||
| 221 | - | - | ||
| 58 | - | - | ||
| 50 | - | - | ||
| 434 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15 t sitten · MuokattuFrom Carlsquare after Q1: Taken from financial estimates, Carlsquare claims despite low 2025 sales that "gross net sales" (the sales of PancreaSure, presumably) will increase 361 % (2026E) in their analysis. Then an estimate of 447 % (2027E). After that, they are guessing about the future with "Net Sales 2028E of 55 mSEK" and "Net Sales 2029E of 110 mSEK" Part of their view that is perhaps the most interesting. But Carlsquare probably has little impact on the time perspective. "Discussions with potential commercialisation partners a key priority OPEX was flat and lower than expected, at SEK -19m. Cash burn was below previous company guidance, and Immunovia reiterates that its cash balance will secure its working capital needs through Q3 2026. In the short term, this allows for increased clinical activity, such as the new registry study, ASSURE, which assesses the clinical utility of PancreaSure. The aim is to generate additional evidence supporting the process of establishing reimbursement. By the end of Q1, the cash position was SEK 56m, down from SEK 77m in the previous quarter. There are clear signals that Immunovia is giving business development and partnerships activities higher priority. Management mentions discussions with over a dozen prospective U.S. commercialisation partners. Also, the board is proposing an incentive program tied to certain “exit events” including outlicensing of PancreaSure or significant ownership changes in Immunovia. We believe proven commercial traction for PancreaSure is likely a key parameter for successful partnering on favourable terms." https://mfn.se/a/carlsquare/research-update-immunovia-q1-2026-initial-commercialisation-phase-on-track They summarize other aspects as well- ·2 päivää sitten · MuokattuI wonder where we're headed over the summer. It's only May, after all. Now, the years won't be alike. But we should be closer now (to what everyone is waiting for) than at the same time in 2025. But back then, the stock wasn't burdened by yet another new emission, which happened in autumn 2026. Summer 2025 started a bit slowly, but sometime in June-July, it really picked up speed. I remember I was 100 thousand in profit at the end of August back then. But, I never realized that, so those 100 thousand vanished and turned into deep red losses instead over autumn 2025.
- ·8.5. · Muokattu57+ minutes into webcast Commercial partner, what is most important: * Must have a strong presence among the medical teams that need the test * Otherwise, that the partner offers a good position to be able to use the test And what other resources they can offer * And what strategic position they can offer. E.g. * Other tests that "pair well with PancreaSure" What does Immunovia do with this question about partner: * Engages in industry conferences (assume health 😜) * Scientific conferences allow them to meet with their "Research and development (R&D) teams * Much of the activity consists of business activities such as sharing information as soon as Immunovia has it and setting up phone calls with them to keep them informed about what they are doing and discuss opportunities
- ·8.5. · Muokattu56 minutes into the webcast after the Asia question to get this elaborated: * Japan and China are the relevant cases it eventually leads to. * Those markets really focus on early detection ("detection") * They have groups with close ties to government that are very focused on early detection * In addition, pancreatic cancer is more prevalent in those nations than in the rest of the world * I.e. a nice financial opportunity * Discussions are being held with companies that have diagnostic capacity in these countries * Next week Jeff travels to China to speak at an "early detection conference" AND.. AND they will have discussions with potential partners there
- ·8.5. · MuokattuLater in the webcast after Carlsquare was finished: New York approval at 54 minutes: * NY has already inspected the laboratory. * NY is going through some data now * Immunovia has another submission, which is coming at the end of May to NY * Jeff expects approval within the next few months * Jeff says the good news is that the laws in NY have changed, and that Immunovia is able to use the test in the meantime. * They have started "to line up some clinics in NY, and to do some limited testing", which will accelerate when they receive the NY approval
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
5 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sitten · MuokattuFrom Carlsquare after Q1: Taken from financial estimates, Carlsquare claims despite low 2025 sales that "gross net sales" (the sales of PancreaSure, presumably) will increase 361 % (2026E) in their analysis. Then an estimate of 447 % (2027E). After that, they are guessing about the future with "Net Sales 2028E of 55 mSEK" and "Net Sales 2029E of 110 mSEK" Part of their view that is perhaps the most interesting. But Carlsquare probably has little impact on the time perspective. "Discussions with potential commercialisation partners a key priority OPEX was flat and lower than expected, at SEK -19m. Cash burn was below previous company guidance, and Immunovia reiterates that its cash balance will secure its working capital needs through Q3 2026. In the short term, this allows for increased clinical activity, such as the new registry study, ASSURE, which assesses the clinical utility of PancreaSure. The aim is to generate additional evidence supporting the process of establishing reimbursement. By the end of Q1, the cash position was SEK 56m, down from SEK 77m in the previous quarter. There are clear signals that Immunovia is giving business development and partnerships activities higher priority. Management mentions discussions with over a dozen prospective U.S. commercialisation partners. Also, the board is proposing an incentive program tied to certain “exit events” including outlicensing of PancreaSure or significant ownership changes in Immunovia. We believe proven commercial traction for PancreaSure is likely a key parameter for successful partnering on favourable terms." https://mfn.se/a/carlsquare/research-update-immunovia-q1-2026-initial-commercialisation-phase-on-track They summarize other aspects as well
- ·2 päivää sitten · MuokattuI wonder where we're headed over the summer. It's only May, after all. Now, the years won't be alike. But we should be closer now (to what everyone is waiting for) than at the same time in 2025. But back then, the stock wasn't burdened by yet another new emission, which happened in autumn 2026. Summer 2025 started a bit slowly, but sometime in June-July, it really picked up speed. I remember I was 100 thousand in profit at the end of August back then. But, I never realized that, so those 100 thousand vanished and turned into deep red losses instead over autumn 2025.
- ·8.5. · Muokattu57+ minutes into webcast Commercial partner, what is most important: * Must have a strong presence among the medical teams that need the test * Otherwise, that the partner offers a good position to be able to use the test And what other resources they can offer * And what strategic position they can offer. E.g. * Other tests that "pair well with PancreaSure" What does Immunovia do with this question about partner: * Engages in industry conferences (assume health 😜) * Scientific conferences allow them to meet with their "Research and development (R&D) teams * Much of the activity consists of business activities such as sharing information as soon as Immunovia has it and setting up phone calls with them to keep them informed about what they are doing and discuss opportunities
- ·8.5. · Muokattu56 minutes into the webcast after the Asia question to get this elaborated: * Japan and China are the relevant cases it eventually leads to. * Those markets really focus on early detection ("detection") * They have groups with close ties to government that are very focused on early detection * In addition, pancreatic cancer is more prevalent in those nations than in the rest of the world * I.e. a nice financial opportunity * Discussions are being held with companies that have diagnostic capacity in these countries * Next week Jeff travels to China to speak at an "early detection conference" AND.. AND they will have discussions with potential partners there
- ·8.5. · MuokattuLater in the webcast after Carlsquare was finished: New York approval at 54 minutes: * NY has already inspected the laboratory. * NY is going through some data now * Immunovia has another submission, which is coming at the end of May to NY * Jeff expects approval within the next few months * Jeff says the good news is that the laws in NY have changed, and that Immunovia is able to use the test in the meantime. * They have started "to line up some clinics in NY, and to do some limited testing", which will accelerate when they receive the NY approval
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 685 | - | - | ||
| 221 | - | - | ||
| 58 | - | - | ||
| 50 | - | - | ||
| 434 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
UUTTA
5 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sitten · MuokattuFrom Carlsquare after Q1: Taken from financial estimates, Carlsquare claims despite low 2025 sales that "gross net sales" (the sales of PancreaSure, presumably) will increase 361 % (2026E) in their analysis. Then an estimate of 447 % (2027E). After that, they are guessing about the future with "Net Sales 2028E of 55 mSEK" and "Net Sales 2029E of 110 mSEK" Part of their view that is perhaps the most interesting. But Carlsquare probably has little impact on the time perspective. "Discussions with potential commercialisation partners a key priority OPEX was flat and lower than expected, at SEK -19m. Cash burn was below previous company guidance, and Immunovia reiterates that its cash balance will secure its working capital needs through Q3 2026. In the short term, this allows for increased clinical activity, such as the new registry study, ASSURE, which assesses the clinical utility of PancreaSure. The aim is to generate additional evidence supporting the process of establishing reimbursement. By the end of Q1, the cash position was SEK 56m, down from SEK 77m in the previous quarter. There are clear signals that Immunovia is giving business development and partnerships activities higher priority. Management mentions discussions with over a dozen prospective U.S. commercialisation partners. Also, the board is proposing an incentive program tied to certain “exit events” including outlicensing of PancreaSure or significant ownership changes in Immunovia. We believe proven commercial traction for PancreaSure is likely a key parameter for successful partnering on favourable terms." https://mfn.se/a/carlsquare/research-update-immunovia-q1-2026-initial-commercialisation-phase-on-track They summarize other aspects as well
- ·2 päivää sitten · MuokattuI wonder where we're headed over the summer. It's only May, after all. Now, the years won't be alike. But we should be closer now (to what everyone is waiting for) than at the same time in 2025. But back then, the stock wasn't burdened by yet another new emission, which happened in autumn 2026. Summer 2025 started a bit slowly, but sometime in June-July, it really picked up speed. I remember I was 100 thousand in profit at the end of August back then. But, I never realized that, so those 100 thousand vanished and turned into deep red losses instead over autumn 2025.
- ·8.5. · Muokattu57+ minutes into webcast Commercial partner, what is most important: * Must have a strong presence among the medical teams that need the test * Otherwise, that the partner offers a good position to be able to use the test And what other resources they can offer * And what strategic position they can offer. E.g. * Other tests that "pair well with PancreaSure" What does Immunovia do with this question about partner: * Engages in industry conferences (assume health 😜) * Scientific conferences allow them to meet with their "Research and development (R&D) teams * Much of the activity consists of business activities such as sharing information as soon as Immunovia has it and setting up phone calls with them to keep them informed about what they are doing and discuss opportunities
- ·8.5. · Muokattu56 minutes into the webcast after the Asia question to get this elaborated: * Japan and China are the relevant cases it eventually leads to. * Those markets really focus on early detection ("detection") * They have groups with close ties to government that are very focused on early detection * In addition, pancreatic cancer is more prevalent in those nations than in the rest of the world * I.e. a nice financial opportunity * Discussions are being held with companies that have diagnostic capacity in these countries * Next week Jeff travels to China to speak at an "early detection conference" AND.. AND they will have discussions with potential partners there
- ·8.5. · MuokattuLater in the webcast after Carlsquare was finished: New York approval at 54 minutes: * NY has already inspected the laboratory. * NY is going through some data now * Immunovia has another submission, which is coming at the end of May to NY * Jeff expects approval within the next few months * Jeff says the good news is that the laws in NY have changed, and that Immunovia is able to use the test in the meantime. * They have started "to line up some clinics in NY, and to do some limited testing", which will accelerate when they receive the NY approval
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 685 | - | - | ||
| 221 | - | - | ||
| 58 | - | - | ||
| 50 | - | - | ||
| 434 | - | - |
Välittäjätilasto
Dataa ei löytynyt